CA3003760A1 - Drug for inhibiting adipose cell differentiation and insulin resistance - Google Patents

Drug for inhibiting adipose cell differentiation and insulin resistance Download PDF

Info

Publication number
CA3003760A1
CA3003760A1 CA3003760A CA3003760A CA3003760A1 CA 3003760 A1 CA3003760 A1 CA 3003760A1 CA 3003760 A CA3003760 A CA 3003760A CA 3003760 A CA3003760 A CA 3003760A CA 3003760 A1 CA3003760 A1 CA 3003760A1
Authority
CA
Canada
Prior art keywords
group
mice
fat diet
mes
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3003760A
Other languages
English (en)
French (fr)
Inventor
Yongzhang Luo
Hui Wang
Hui Li
Xinan Lu
Yan Fu
Shunli ZHAN
Daifu ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of CA3003760A1 publication Critical patent/CA3003760A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3003760A 2014-11-03 2015-11-03 Drug for inhibiting adipose cell differentiation and insulin resistance Pending CA3003760A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410610777 2014-11-03
CN201410610777.X 2014-11-03
CN201510021469.8 2015-01-15
CN201510021469 2015-01-15
PCT/CN2015/093726 WO2016070798A1 (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Publications (1)

Publication Number Publication Date
CA3003760A1 true CA3003760A1 (en) 2016-05-12

Family

ID=55908589

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3003760A Pending CA3003760A1 (en) 2014-11-03 2015-11-03 Drug for inhibiting adipose cell differentiation and insulin resistance

Country Status (7)

Country Link
US (2) US20180015148A1 (https=)
EP (1) EP3246043A4 (https=)
JP (2) JP2018501195A (https=)
CN (2) CN107148277B (https=)
AU (1) AU2015342324B2 (https=)
CA (1) CA3003760A1 (https=)
WO (1) WO2016070798A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6896636B2 (ja) * 2015-02-13 2021-06-30 清華大学Ｔｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ 組換えタンパク質薬の分子設計
EP3539570B1 (en) 2016-11-10 2022-04-13 Beijing Protgen Ltd. Pegylated endostatin analogue and application thereof
US10276161B2 (en) 2016-12-27 2019-04-30 Google Llc Contextual hotwords

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306819B1 (en) * 1997-10-31 2001-10-23 Massachusetts Institute Of Technology Method for regulating size of vascularized normal tissue
AU2002323543A1 (en) * 2001-09-07 2003-03-24 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
CN101596320B (zh) * 2006-01-20 2013-01-09 清华大学 一种治疗肿瘤的药物及其应用
CN103083681A (zh) * 2006-01-20 2013-05-08 清华大学 一种治疗肿瘤的药物及其应用
EP2214709A4 (en) * 2007-11-08 2011-05-11 Univ Utah Res Found USE OF ANGIOGENESIS ANTAGONISTS IN DISEASES WITH ANOMAL VENEER PREPARATION
CN101219206A (zh) * 2008-02-01 2008-07-16 山东先声麦得津生物制药有限公司 重组人血管内皮抑制素在制药中的应用
CN102698270B (zh) * 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
MX2013011294A (es) * 2011-03-30 2014-10-06 Univ Texas Metodos y composiciones para dirigir celulas adiposas en mamiferos.
JP6336389B2 (ja) * 2011-09-09 2018-06-06 チンファ ユニヴァーシティＴｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ Ａｔｐ結合部位に変異を有するエンドスタチン変異体

Also Published As

Publication number Publication date
US20180015148A1 (en) 2018-01-18
WO2016070798A1 (zh) 2016-05-12
EP3246043A4 (en) 2018-09-05
JP2018501195A (ja) 2018-01-18
CN107148277A (zh) 2017-09-08
CN107148277B (zh) 2022-03-22
AU2015342324B2 (en) 2021-08-19
EP3246043A9 (en) 2018-03-14
US20220409703A1 (en) 2022-12-29
CN114558111A (zh) 2022-05-31
EP3246043A1 (en) 2017-11-22
AU2015342324A1 (en) 2017-06-29
JP2020172546A (ja) 2020-10-22
JP7227197B2 (ja) 2023-02-21

Similar Documents

Publication Publication Date Title
US20220409703A1 (en) Drug for inhibiting adipose cell differentiation and insulin resistance
JP6813156B2 (ja) 抗肥満及び抗糖尿作用を有するペプチド及びその用途
EP3189849B1 (en) Peptides for preventing or treating obesity
CN111494605B (zh) Creg蛋白用于预防或治疗阿霉素心肌损伤的医药用途
WO2016197592A1 (zh) 一种长链非编码rna hnf1a-as1在制备治疗人体恶性实体瘤药物中的应用
CN119013405A (zh) 包含utr的核酸构建体及其应用
Deane et al. Aquaporin 1a expression in gill, intestine, and kidney of the euryhaline silver sea bream
Yang et al. Pigment epithelium-derived factor improves TNFα-induced hepatic steatosis in grass carp (Ctenopharyngodon idella)
Wang et al. Leptin gene protects against cold stress in Antarctic toothfish
CN111808186B (zh) 一种人源性分泌型fndc5蛋白及其制备方法和用途
CN107961382B (zh) miR-1252在制备治疗特应性皮炎的药物中的应用
CN117100742B (zh) Rhodiolin在制备治疗人甲状腺乳头状癌药物中的应用
CN112680390B (zh) 重组微生物、其代谢物、及其用于治疗或/及预防脂肪肝及心血管疾病的用途
WO2025247200A1 (zh) 桑提取物在制备治疗和/或预防视网膜病变的药物中的用途
CN116904577A (zh) 一种Bdh1蛋白在糖尿病心脏保护中的应用及基因药物
HK1240832B (en) Peptides for preventing or treating obesity
JP2003089636A (ja) 熱ショック蛋白質の合成抑制及び機能抑制剤
CN103705523A (zh) 前列环素及类似物在体外抑制心肌成纤维细胞增殖的应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201103

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241016

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - SMALL

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241104

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241104

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250214

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250628

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250628

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - SMALL

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226